TNF and obesity due to melanocortin 4 receptor deficiency: Gratacós et al. link obesity to an increased risk of treatment failure in PsA [52], particularly with anti-TNF drugs, with obese patients showing a lower probability of achieving and maintaining minimal disease activity (MDA).